RISE program at NMSU, highlighting success

Posted on October 21st, 2014 in Anita Bandrowski, Author, General information, News & Events | No Comments »

We at NIF were very fortunate to have hosted the director of the RISE program from NMSU, Elba Serrano this summer attempting to develop coursework and improve outreach to students and faculty at New Mexico State. We believe that the scientific workforce in the coming decade will need to be aware of computational problems, statistics and bioinformatics resources. It is critical that we train this workforce and the RISE program is exactly the right place to start.

We are thrilled that this collaboration has resulted in a set of workshops that will be held in the spring and a set of course modifications for NMSU students to start becoming aware of bioinformatics in the fall.

A news story outlining the success of the program can be found below; a 90% promotion rate of minority and disadvantaged students is truly something to be proud of!
http://www.lcsun-news.com/News/ci_26759056/Rally-honors-achievements-of-NMSU-RISE-program-for-science-students

 

Please join us for a webinar discussing Neurostars: A Q&A platform for neuroscience

Posted on October 20th, 2014 in Anita Bandrowski, Author, News & Events, Webinar Announcement | No Comments »

Next week we kick off the fall webinar series, with Dr. Satrajit Ghosh from the Massachusetts Institute of Technology. Dr. Ghosh is a research scientist at the mcgovern institute for brain research and an assistant professor at harvard medical school. He will talk about Neurostars and Biostars.

Neurostars (neurostars.org) and Biostars (biostars.org) are sibling question and answer platforms for neuroscience and bioinformatics communities. Based on the successful StackOverflow model, these platforms provide a voting mechanism, a modern user-interface, integrated search, and personalization characteristics that are typically not available in traditional mailing lists or forums. It also supports facilities for data discovery links and discussion using the bittorrent mechanism, and is now part of the mozilla science lab (http://collaborate.mozillascience.org/projects/neurostars). Neurostars is maintained and run by the International Neuroinformatics Coordinating Facilities (INCF) with community input and support.

This webinar will go over some of the basic operations, some features that are only available on these platforms, and finish with a near term roadmap of new features under consideration.

 

Available here:

Where: https://www.youtube.com/watch?v=4Nw8YXuJ1a4&feature=youtu.be
When: Anytime!

Network of BioThings Hackathon – Nov 7-9

Posted on October 16th, 2014 in Anita Bandrowski, News & Events | No Comments »

The Network of BioThings is sponsoring a hackathon.
NoB Hackathon poster

Come one, come all.
Mainly though, sign up because space is fairly limited.

ISIS PHARMACEUTICALS REPORTS DATA FROM ISIS-SMNRX PHASE 2 STUDIES IN INFANTS AND CHILDREN WITH SPINAL MUSCULAR ATROPHY

Posted on October 10th, 2014 in Anita Bandrowski, General information, News & Events | No Comments »

NIF applauds ISIS pharmaceuticals, the press release is below. This is an event, unfortunately too rare, where neuroscience research is successfully pushed from the bench to a clinical application giving an option for treatment of babies diagnosed with this neuro-skeletal disorder. We salute the SMA foundation, which has been pushing scientists, clinicians and the public for years, breaking down the obstacles to move basic science and the pharmaceutical industry toward a collaboration around a rare genetic disease.

—————————-Press Release Below ————————————
Phase 3 ENDEAR study in infants with SMA enrolling; on track to initiate Phase 3 study in children with SMA later this year

Isis to host a webcast at 11:30 a.m. EDT on Friday, October 10
CARLSBAD, Calif., October 10, 2014 – Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) today provided an update on its ongoing open-label Phase 2 clinical studies of ISIS-SMNRx in infants and children with spinal muscular atrophy (SMA) at the 19th International World Muscle Society (WMS) Congress in Berlin, Germany. Isis is currently treating infants with SMA with ISIS-SMNRx in a Phase 3 study called ENDEAR, and plans to initiate a second Phase 3 study, called CHERISH, in children with SMA later this year.
“I am encouraged with the totality of the data presented today, which show that median event-free ages for SMA infants in both the 6 mg and 12 mg cohorts compare favorably to that observed in a recent natural history study. These data combined with the safety and tolerability profile observed to date support my enthusiasm to further evaluate ISIS-SMNRx in a Phase 3 study in infants with Type I SMA,” said Richard Finkel, M.D., chief, division of neurology, department of pediatrics, Nemours Children’s Hospital. “Often infants with Type I SMA succumb to early death due to progressive weakness of the muscles responsible for breathing and feeding. In the PNCR natural history study, for which I was the lead investigator, in a group of untreated patients similar to those in the Isis Phase 2 study, the median event-free age was 10.5 months, with less than 20% of patients event free at 18 months. In addition to the positive data on event-free survival, substantial and persistent increases in muscle function as measured by the CHOP INTEND and Hammersmith Infant Neurological Examination were also observed in ISIS-SMNRx-treated infants up to 9 months on study. This is an important finding because in general, infants with Type I SMA decline over time in their motor function as reflected in scores on these tests.”
 
Event-free survival data from Phase 2 study in infants with SMA
In the Phase 2 study in infants with SMA, a total of 20 infants were dosed as of Sept 1st, four infants in the 6 mg cohort and 16 infants in the 12 mg cohort. As of April 7, 2014, the date of Isis’ previous data update, the per protocol efficacy populations (PPEP) (patients who completed the three dose induction regimen in the study) constituted four patients in the 6 mg and seven patients in the 12 mg dose cohorts,. As of September 2, 2014, the date for this data update, the PPEP constituted four patients in the 6 mg and 12 patients in the 12 mg dose cohorts.
In the 6 mg cohort:
•          No patients have had an event (death or permanent ventilation) since April 2014. As of September 2, 2014, there have been two events (one accidental death and one permanent ventilation) in the 6 mg cohort.
•          Isis previously reported a median event-free age of 14 months for the infants in the PPEP on April 7, 2014. The median event-free age on September 2, 2014 for the infants in this group is now 16.3 months.
In the 12 mg cohort:
•          Dosing in the 12 mg cohort began five months after the initiation of dosing for the 6 mg cohort. As a result, the patients in the 12 mg cohort have participated in the study for a shorter time than those in the 6 mg cohort. As of April 7, the PPEP in the 12 mg dose cohort contained 7 infants. As ofSeptember 2, the PPEP for the 12 mg dose cohort contained 12 infants, which included an additional five infants who had more recently entered the study.
•          Isis previously reported a median event-free age of 9.6 months for the infants who constituted the 12 mg PPEP as of April 7, 2014. The median event-free age at September 2, 2014 for these infants is now 13.8 months.
•          The median event-free age of the 12 infants in the PPEP as of September 2, 2014 for the 12 mg cohort is 11.6 months. Of these 12 infants, nine are alive without the need for permanent ventilation.
•          As of September 2, 2014, there have been four events (one permanent ventilation and three deaths, all related to respiratory infections) in the 16 infants from the 12 mg cohort.
Increases in muscle function scores in this study in infants with SMA
Measures of muscle function are also being assessed in this study. Increases in muscle function scores were observed in infants in both dosing cohorts using the Children’s Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND), a motor assessment test that is used to evaluate muscle strength in infants with SMA.
•          Increases in CHOP INTEND scores occurred in a majority of infants in the study. Infants in the PPEP from the 6 mg and 12 mg cohorts combined showed mean increases from baseline in CHOP INTEND of 9.3 points with 14 of the 16 infants showing an increase in CHOP INTEND scores.
•          Infants from the 12 mg dose cohort PPEP showed mean increases from baseline in CHOP INTEND of 11.7 points with 11 of the 12 infants showing an increase in CHOP INTEND scores.
Developmental milestones are also being examined in this study using the Motor Milestones portion of the Hammersmith Infant Neurological Examination, with 14 out of the 16 infants in the combined PPEP exhibiting improvements in motor milestones.
The safety and tolerability profile of ISIS-SMNRx to date supports continued development. As of September 2, 2014, 20 infants have been exposed to doses of either 6 mg or 12 mg of ISIS-SMNRx for a total of 67 intrathecal injections. The lumbar puncture procedure in SMA infants has been well tolerated and shown to be feasible. In all infants dosed, there have been no drug-related serious adverse events. Most of the adverse events (non-SAEs) have been mild or moderate in severity and not related to drug. There were no changes in the safety profile with repeated doses of ISIS-SMNRx.
Clinical data on ISIS-SMNRx Mechanism of Action
Today, Isis reported the results from an analysis of spinal cord tissue samples from autopsies showing that ISIS-SMNRx is distributed throughout the central nervous system. The results of these analyses also showed greater levels of full length SMN2 mRNA and full length SMN protein in tissues in ISIS-SMNRx-treated SMA infants compared to the levels of SMN2 mRNA and full length SMN protein in the tissues analyzed from untreated SMA infants. These analyses were conducted on tissue samples collected in three infants who had received three or more doses of ISIS-SMNRx and were compared to tissue samples from four untreated SMA infants and three infants without SMA at a similar age range.
•          Analysis of spinal cord tissue showed that ISIS-SMNRx concentration in spinal cord tissues was greater than the concentration that resulted in biological activity in animal studies. ISIS-SMNRx was found in multiple segments of the spinal cord and brain and in motor neurons.
•          Greater level of full-length (containing exon 7) SMN2 mRNA was observed in the spinal cord and brain tissue of ISIS-SMNRx-treated SMA infants compared to the level of full-length SMN2 mRNA in the untreated SMA infants.
•          In patients treated with ISIS-SMNRx, greater amounts of SMN protein were observed in the spinal cord compared to the amount of SMN protein observed in the untreated SMA infants.
•          SMN protein was observed in neurons of tissues analyzed in ISIS-SMNRx-treated SMA infants in which ISIS-SMNRx was present.
“The results on ISIS-SMNRx presented today forms an encouraging profile of a potential new therapy for patients with SMA,” continued Dr. Finkel. “The consistency of observations in event-free survival, CHOP-INTEND and development milestones, combined with the clinical data supporting the mechanism of action by which ISIS-SMNRx was designed to act, creates strong support to continue evaluation of ISIS-SMNRx.”
“We are encouraged that we have been able to evaluate both the distribution of ISIS-SMNRx in spinal cord tissues and motor neurons, and the levels of full length SMN protein in the spinal cord of ISIS-SMNRx-treated infants. We are very fortunate to have access to these tissue samples, and thankful to the families who have allowed us to use them to advance the study of SMA and ISIS-SMNRx. Access to these tissues has enabled us to confirm what we observed in our earlier preclinical work; that ISIS-SMNRx is broadly distributed throughout the central nervous system of ISIS-SMNRx-treated infants. We are also pleased to observe that the levels of ISIS-SMNRx in tissues analyzed from ISIS-SMNRx-treated infants are greater than the concentrations at which we observed biological activity in our animal studies. We are also encouraged with the greater levels of full-length SMN2 mRNA and commensurate increases in SMN protein we observed in tissues analyzed from ISIS-SMNRx-treated SMA infants as compared to the levels of full-length SMN2 mRNA and SMN protein we observed in tissues analyzed from untreated SMA infants,” said C. Frank Bennett, Ph.D., senior vice president of research at Isis Pharmaceuticals.
Results from Phase 2 study in children with SMA
In the ongoing, open-label study in children with SMA, increases in muscle function scores, as measured by the Hammersmith Functional Motor Scale-Expanded (HFMSE), were observed in children treated with multiple-doses of ISIS-SMNRx. As previously reported in April 2014, children in the 3 mg, 6 mg and 9 mg cohorts achieved mean increases from baseline of 1.5, 2.3 and 3.7 points, respectively, 9 months following their first dose (six months after last dose). Further evaluation of these children showed that the previously observed mean increases in muscle function scores continued to show increases from baseline for an extended period after their last dose with mean increases from baseline of 1.7, 3.2 and 2.3, respectively, eight to 13 months after last dose.
Increases in two additional functional tests were also observed eight to 13 months after last dose in the six-minute walk test (6MWT) and the upper limb mobility (ULM) test. In the 6MWT, performed with 10 ambulatory children, a mean increase of 24.4 meters was observed 12 to 16 months after the patients’ baseline visits, compared to the previously reported increase of 22.7 meters at nine months. In the ULM test, a mean increase of 3.1 points was observed 11 to 16 months after the patients’ baseline visits, compared to the previously reported increase of 2.3 points at nine months.
The safety and tolerability profile of ISIS-SMNRx continues to support continued development. As of September 2, 2014, 56 children have been exposed to doses ranging from 1 mg to 12 mg of ISIS-SMNRx. The majority of these children have received multiple doses of drug and in total 183 doses of ISIS-SMNRx have been administered. The lumbar puncture procedure in SMA children has been well tolerated and shown to be feasible. In all children dosed, there have been no drug-related serious adverse events. Most of the adverse events (non-SAEs) have been mild or moderate in severity and not related to drug. There were no changes in the safety profile with repeated doses of ISIS-SMNRx.
“SMA is a heartbreaking disease. Children with SMA are bright and engaging, but due to progressive muscle weakness, grow weaker over time and suffer a decline in their physical abilities. Because of the inevitable gradual decline that patients with SMA exhibit, I am encouraged with the consistency of the muscle function scores in these children. Not only do these children experience increases in muscle function scores, even after a single dose of ISIS-SMNRx, but it now appears that these increases can be sustained for a significant time after dosing,” said Basil Darras, M.D., professor of neurology, director of clinical neurology at the Boston Children’s Hospital and Harvard Medical School.
“The consistency of the increases in muscle function scores across different SMA patient populations, including both children and infants with SMA, and the dose-and time-dependency of these increases is encouraging. The observation of increases in SMN protein in the spinal cord in tissues analyzed from ISIS-SMNRx-treated infants, suggest that ISIS-SMNRx is acting by the mechanism of action through which it was designed to act,” concluded Dr. Bennett.
Investor Event
At 11:30 a.m. Eastern Time, Oct. 10, 2014, Isis will conduct a webcast to discuss ISIS-SMNRx data presented at the WMS. A live audio webcast of the presentation will be available on the “Investors & Media” section of the Company’s website, http:www.isispharm.com. A replay will be available for a limited time. The slides presented at the WMS meeting are available on Isis’ website at http://www.isispharm.com.
ABOUT ISIS-SMNRx
ISIS-SMNRx is designed to alter the splicing of a closely related gene (SMN2) to increase production of fully functional SMN protein. The United States Food and Drug Administration granted orphan drug status and fast track designation to ISIS-SMNRx for the treatment of patients with SMA. Isis is currently in collaboration with Biogen Idec to develop and potentially commercialize the investigational compound, ISIS-SMNRx, to treat all types of SMA. Under the terms of the January 2012 agreement, Isis is responsible for global development and Biogen Idec has the option to license the compound until completion of the first successful Phase 2/3 study or the completion of two Phase 2/3 studies.
ISIS-SMNRx is being evaluated in a pivotal Phase 3 study, ENDEAR, in infants with SMA. The ENDEAR study is a randomized, double-blind, sham-procedure controlled thirteen month study in approximately 110 infants diagnosed with SMA. The study will evaluate the efficacy and safety of a 12 mg dose of ISIS-SMNRxwith a primary endpoint of survival or permanent ventilation. Additional efficacy endpoints are also included in the study. For further study information, please visit www.clinicaltrials.gov and search for ISIS-SMNRx or the identifier number NCT02193074 or visit the ISIS-SMNRx study site at www.smastudy.com.
Isis acknowledges support from the following organizations for ISIS-SMNRx: Muscular Dystrophy Association, SMA Foundation, Cure SMA and intellectual property licensed from Cold Spring Harbor Laboratory and the University of Massachusetts Medical School.
ABOUT SMA
SMA is a severe genetic disease that affects approximately 30,000-35,000 patients in the United States, Europe and Japan. SMA is caused by a loss of, or defect in, the survival motor neuron 1 (SMN1) gene leading to a decrease in the survival motor neuron (SMN) protein. SMN is critical to the health and survival of nerve cells in the spinal cord responsible for neuromuscular growth and function. One in 50 people, the equivalent of about six million people in the United States, are carriers of a defective SMN1 gene, which is unable to produce fully functional SMN protein. Carriers experience no symptoms and do not develop the disease. However, when both parents are carriers, there is a one in four chance that their child will have SMA. The severity of SMA correlates with the amount of SMN protein. Infants with Type I SMA, the most severe form of the disease, produce very little SMN protein and have a life expectancy of less than two years. Children with Type II have greater amounts of SMN protein but still have a shortened lifespan and are never able to stand independently. Children with Type III have a normal lifespan but accumulate life-long physical disabilities as they grow.
ABOUT ISIS and BIOGEN IDEC
Biogen Idec and Isis have established four collaborations focused on leveraging antisense technology to advance the treatment of neurological and neuromuscular disorders. This alliance combines Isis’s expertise in antisense technology to evaluate potential neurological targets and discover antisense drugs with Biogen Idec’s capability to develop therapies for neurological disorders. Isis is primarily responsible for drug discovery and early development of antisense therapies. Biogen Idec has the option to license each antisense program at a particular stage in development. Current development-stage programs include antisense drugs to treat SMA, ISIS-SMNRx, and myotonic dystrophy type 1, ISIS-DMPKRx.
ABOUT ISIS PHARMACEUTICALS, INC.
Isis is exploiting its leadership position in antisense technology to discover and develop novel drugs for its product pipeline and for its partners. Isis’ broad pipeline consists of 32 drugs to treat a wide variety of diseases with an emphasis on cardiovascular, metabolic, severe and rare diseases, including neurological disorders, and cancer. Isis’ partner, Genzyme, is commercializing Isis’ lead product, KYNAMRO®, in the United States for the treatment of patients with HoFH. Isis’ patents provide strong and extensive protection for its drugs and technology. Additional information about Isis is available at www.isispharm.com.
ISIS PHARMACEUTICALS’ FORWARD-LOOKING STATEMENT
This press release includes forward-looking statements regarding Isis’ alliance with Biogen Idec, the discovery, development, activity, therapeutic and commercial potential and safety of ISIS-SMNRx and the discovery, development and therapeutic potential of an antisense drug for the treatment of spinal muscular atrophy. Any statement describing Isis’ goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs. Isis’ forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although Isis’ forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Isis. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Isis’ programs are described in additional detail in Isis’ annual report on Form 10-K for the year ended December 31, 2013, and its most recent quarterly report on Form 10-Q, which are on file with the SEC. Copies of these and other documents are available from the Company.
In this press release, unless the context requires otherwise, “Isis,” “Company,” “we,” “our,” and “us” refers to Isis Pharmaceuticals and its subsidiaries.
Isis Pharmaceuticals® is a registered trademark of Isis Pharmaceuticals, Inc. KYNAMRO® is a registered trademark of Genzyme Corporation.
Isis Pharmaceuticals’ Contacts:
D. Wade Walke, Ph.D.                                                 Amy Blackley, Ph.D.
Vice President, Corporate Communications and          Associate Director, Corporate Communications
Investor Relations                                                        760-603-2772
###

Introducing the Aging Portal

Posted on October 8th, 2014 in Anita Bandrowski, Data Spotlight | No Comments »

The Neuroscience Information Framework, has been asked many times “how can we sort through this dizzying amount of data?” to which we have never had a great answer until now. With SciCrunch, a shared portal infrastructure that allows users to create their own portals into subsets of data, NIF has created a dedicated subset of resources funded by and of interest to the aging research community.

The portal can be found here: http://scicrunch.com/Aging

 

The NIA funded a small award to pull interesting resources out of the main, at times overwhelming quantity, of NIF resources into their own portal, and we have done this for 14 databases including the following that were brought in specifically for the portal:

Aging Genes and Interventions Database

AnAge

Human Mortality Database

Lifespan Observation Database

 

Other resources that were already present in the Data Federation such as Aging Genes Database and Clinical Trials. However, we hypothesize that with many databases only subsets of the data are relevant to aging, for example our integrated Clinical Trials data are relevant to aging when the population is aged. Similarly Gene Ontology Annotations for aging-related genes are included. If this is not a valid assumption, we would love to hear from you.

We hope that this portal is a useful tool for aging researchers, who can start looking for aging relevant data or databases funded by the NIA by looking at the subset of community databases and hopefully recover reasonable subsets of data. However, if the subset of data is not sufficient for the purposes of the researcher, all of the other databases aggregated by NIF are available and accessible via a fully configured search interface under the “more resources” tab.

 

Happy Data Hunting!

NIF now pleased to serve more electrophysiology data

Posted on September 30th, 2014 in Anita Bandrowski, Data Spotlight, News & Events | 1 Comment »

For years, physiology has been lagging far behind anatomy as data sharing is still in infancy in that community as opposed to being fairly standard now in neuro-anatomy.

We are pleased to announce that the Physiobank registry resource from MIT, containing data from a set of physiology experiments has been added to the NIF Data Federation.

 

This brings us to 6 sources of data (anatomy is still winning, but perhaps we can change that)

CRCNS, a repository of e-phys data (patch clamp mostly)

NeuroElectro, a rather large listing of cellular properties mined from e-phys papers

NeuronDB, a curated set of e-phys properties of known cell types including currents, receptors and transmitters

EEG-base, a repository of EEG data

Neurodatabase, a repository of extracellular data sets.

 

Note, this list may be incomplete because it does not include Model data, so please see Integrated Models, a virtual database currently indexing computational models from:ModelDBOpen Source BrainSimTK and  CellML.

 

New in NIF! Find your MRI images in NeuroVault

Posted on September 29th, 2014 in Anita Bandrowski, Data Spotlight, News & Events | No Comments »

New to NIF this week is NeuroVault.

NeuroVault is a public repository where researchers can publicly store and share unthresholded statistical brain activation maps produced by MRI and PET studies. Many of the data are also accessible from OpenfMRI.

There are currently 369 images, and we anticipate many more in the coming months.

If you wish to share your data via NeuroVault click here.

Obama wants to hear your 2 cents!

Posted on September 5th, 2014 in Anita Bandrowski, General information, News & Events | 2 Comments »

The White House OSTP is requesting comments on a number of issues, one of which is how the federal government can improve reproducibility in the science it funds: https://www.federalregister.gov/articles/2014/07/29/2014-17761/strategy-for-american-innovation

The overwhelmingly important thing is that the White House receive LOTS of individual comments. A ton of comments is how something like this gets attention, and turns into a White House initiative that has some teeth. That is exactly how the White House came to require that federally-funded research be made publicly accessible — they got 300+ comments, and on a technical issue, that’s a lot.

As a way of furthering issues like open data, open code, pre-registration, etc., do think about sending something to the White House, and telling all of your likeminded colleagues to do so as well. Doesn’t matter if it’s only a one-paragraph email — that still counts.

How to do so: Email: innovationstrategy@ostp.gov. Include [Strategy for American Innovation] in the subject line of the message.

Olympus competition

Posted on September 2nd, 2014 in Anita Bandrowski, General information, News & Events | No Comments »

Olympus would like to invite you to submit several of your images and/or digital video clips to the 2014 Olympus BioScapes Digital Imaging Competition, which will honor extraordinary microscope images of life science subjects. Up to five images or videos can be entered via the Internet. Entries for the contest can be uploaded through a web browser directly to the Olympus servers at the following URL:

http://www.olympusbioscapes.com/enter.asp

The deadline for new entries is September 30, 2014.

The winners of the competition are tentatively scheduled to be published in Scientific American.

A note about the contest: First prize will be Olympus microscope or Camera equipment valued at $5,000. Nine additional winners will also receive valuable prizes from Olympus. Each person entering can submit up to five movies, images, or image sequences. It is not necessary for people entering the competition to be users of Olympus equipment. Winners will be notified in late October, and publicly announced in December, 2014.

Comment requested: Academic credit for reviewing

Posted on August 22nd, 2014 in General information, News & Events | No Comments »

This seems a very interesting blog written by Rebecca Lawrence. The link is below.
I am re-posting it for the NIF community.


Link to original blog: http://blog.f1000research.com/2014/08/22/peer-review-service-recognition-orcid-casrai-recommendations-need-your-feedback/


Laura Paglione (Technical Director, ORCID) and I (Rebecca Lawrence) have been co-chairing the CASRAI Peer Review Services Working Group to look at the best way to recognise referee reports as a formal output in for example an ORCID profile. This project has looked at the peer review of a wide range of outputs from articles (open, closed, pre- and post-publication peer review), to grants, conference abstracts, and the review ofuniversities/faculties/departments.


We have now reviewed options for linking peer review service activities with a person identifier such as ORCID, and developed recommendations for data fields, descriptors, persistence, resolution and citation. We now need your feedback!  We are inviting interested subject experts from all these areas to review and comment on the draft outputs of this working group; the deadline for comments is Friday, September 12th 2014. In order to participate, please follow the instructions below.


1) Access the “Document Details” page here, which will provide information about the document as well as a link to download the file.
2) On the “Document Details” page click the link in the “Name” row to download the document.
3) Once you have reviewed the document, return to the “Document Details” page. Click on “add a comment” on the upper left hand side of the “Document Details” table to open the comment form.
4) Please complete one comment form for each term about which you wish to provide feedback. Commenting follows the steps below:
a) In the “Subject” line, reference the term number to which you are referring in your comment. (Example: D04)
b) Complete the comment box with your first comment.
c) Please ignore the items “Section” and “Item” as you have already addressed these by providing the term number in the Subject line.
d) If you would like to expand upon your comment by providing a proposed solution, please do so in the “Proposed Solution” field. This field is optional.
e) For security reasons, please slide the lock button at the bottom of the form to the right.
f) If you have no other comments to add click “Save” at the bottom of the form. Please note that we strongly prefer for each comment to address only one term at a time.
g) If you are commenting on multiple terms click “Save and add another” at the bottom of the form. Please note that you will not be required to re-enter your contact information for each added comment.

 


We really hope you will take this opportunity to provide your feedback on these recommendations so that we can ensure that the final output successfully achieves the goals of this project: proper recognition of the huge amount of unpaid and often invisible effort researchers put in throughout their careers to the essential task of reviewing the work of others.


I have been co-chairing the CASRAI Peer Review Services Working Group together with Laura Paglione (Technical Director, ORCID) to look at the best way to recognise referee reports as a formal output in for example an ORCID profile. This project has looked at the peer review of a wide range of outputs from articles (open, closed, pre- and post-publication peer review), to grants, conference abstracts, and the review of universities/faculties/departments.


We have now reviewed options for linking peer review service activities with a person identifier such as ORCID, and developed recommendations for data fields, descriptors, persistence, resolution and citation. We now need your feedback! We are inviting interested subject experts from all these areas to review and comment on the draft outputs of this working group; the deadline for comments isFriday, September 12th 2014. In order to participate, please follow the instructions below.

  1. Access the “Document Details” page here, which will provide information about the document as well as a link to download the file.
  2. On the “Document Details” page click the link in the “Name” row to download the document.
  3. Once you have reviewed the document, return to the “Document Details” page. Click on “add a comment” on the upper left hand side of the “Document Details” table to open the comment form.
  4. Please complete one comment form for each term about which you wish to provide feedback. Commenting follows the steps below:
  • In the “Subject” line, reference the term number to which you are referring in your comment. (Example: D04)